Abstract:Rationale: Recent studies indicate that microglial activation and the resulting inflammatory response could be potential targets of adjuvant therapy for ischemic stroke. Many studies have emphasized a well-established function of Annexin-A1 (ANXA1) in the immune system, including the regulation of microglial activation. Nevertheless, few therapeutic interventions targeting ANXA1 in microglia for ischemic stroke have been conducted. In the present study, Tat-NTS, a small peptide developed to prevent ANXA1 from entering the nucleus, was utilized. We discovered the underlying mechanism that Tat-NTS peptide targets microglial ANXA1 to protect against ischemic brain injury. Methods: Preclinical studies of ischemic stroke were performed using an oxygen-glucose deprivation and reperfusion (OGD/R) cell model in vitro and the middle cerebral artery occlusion (MCAO) animal model of ischemic stroke in vivo. Confocal imaging and 3D reconstruction analyses for detecting the protein expression and subcellular localization of microglia in vivo. Co-immunoprecipitation (Co-IP), immunoblotting, ELISA, quantitative real-time PCR (qRT-PCR), Luciferase reporter assay for determining the precise molecular mechanism. Measurement on the cytotoxicity of Tat-NTS peptide for microglia was assessed by CCK-8 and LDH assay. TUNEL staining was used to detect the microglia conditioned medium-mediated neuronal apoptosis. Adeno-associated viruses (AAVs) were injected into the cerebral cortex, striatum and hippocampal CA1 region of adult male Cx3cr1-Cre mice, to further verify the neurofunctional outcome and mechanism of Tat-NTS peptide by TTC staining, the modified Neurological Severity Score (mNSS) test, the open field test (OFT), the novel object recognition task (NORT), the Morris water maze (MWM) test, the long-term potentiation (LTP) and the Transmission electron microscopy (TEM). Results: It was observed that administration of Tat-NTS led to a shift of subcellular localization of ANXA1 in microglia from the nucleus to the cytoplasm in response to ischemic injury. Notably, this shift was accompanied by an increase in ANXA1 SUMOylation in microglia and a transformation of microglia towards an anti-inflammatory phenotype. We confirmed that Tat-NTS-induced ANXA1 SUMOylation in microglia mediated IKKα degradation via NBR1-dependent selective autophagy, then blocking the activation of the NF-κB pathway. As a result, the expression and release of the pro-inflammatory factors IL-1β and TNF-α were reduced in both in vitro and in vivo experiments. Furthermore, we found that Tat-NTS peptide's protective effect on microglia relieved ischemic neuron apoptosis. Finally, we demonstrated that Tat-NTS peptide administration, through induction of ANXA1 SUMOylation in microglia, reduced infarct volume, improved neurological function and facilitated behavioral recovery in MCAO mice. Conclusions: Our study provides evidence for a novel mechanism of Tat-NTS peptide in regulating microglial ANXA1 function and its substantial neuroprotective effect on neurons with ischemic injuries. These findings suggest that Tat-NTS peptides have a high potential for clinical application and may be a promising therapeutic candidate for treating cerebral ischemia.

Neuroprotection Against Transient Focal Cerebral Ischemia and Oxygen–Glucose Deprivation by Interference with GluR6-PSD95 Protein Interaction

Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence.

Neuroprotection of Tat-GluR6-9c Against Neuronal Death Induced by Kainate in Rat Hippocampus Via Nuclear and Non-nuclear Pathways*

Neuroprotection of Preconditioning Against Ischemic Brain Injury in Rat Hippocampus Through Inhibition of the Assembly of GluR6—PSD95—mixed Lineage Kinase 3 Signaling Module Via Nuclear and Non-Nuclear Pathways

Neuroprotection Against Permanent Focal Cerebral Ischemia by Ginkgolides A and B is Associated with Obstruction of the Mitochondrial Apoptotic Pathway Via Inhibition of C‐jun N‐terminal Kinase in Rats

Neuroprotective Effects of Glur6 Antisense Oligodeoxynucleotides on Transient Brain is Chemia/Reperfusion-Induced Neuronal Death in Rat Hippocampal Ca1 Region

Activation of T‐LAK‐cell‐originated Protein Kinase‐mediated Antioxidation Protects Against Focal Cerebral Ischemia–reperfusion Injury

GluR6‐containing KA Receptor Mediates the Activation of P38 MAP Kinase in Rat Hippocampal CA1 Region During Brain Ischemia Injury

Ischemic Postconditioning Relieves Cerebral Ischemia and Reperfusion Injury Through Activating T-LAK Cell–Originated Protein Kinase/Protein Kinase B Pathway in Rats

Overexpression of C-terminal Fragment of Glutamate Receptor 6 Prevents Neuronal Injury in Kainate-Induced Seizure Via Disassembly of GluR6-PSD-95-MLK3 Signaling Module

Postsynaptic Density Protein 95 Antisense Oligodeoxynucleotides Inhibits the Activation of MLK3 and JNK3 Via the GluR6·PSD-95·MLK3 Signaling Module after Transient Cerebral Ischemia in Rat Hippocampus

Tat-NTS peptide protects neurons against cerebral ischemia-reperfusion injury via ANXA1 SUMOylation in microglia

PSD-95 inhibitor Tat-NR2B9c (NA-1) protects the integrity of the blood-brain barrier after transient middle artery occlusion in rats by downregulating matrix metalloprotease-9 and upregulating endothelial nitric oxide synthase

Neuroprotection of GluR5-containing Kainate Receptor Activation against Ischemic Brain Injury through Decreasing Tyrosine Phosphorylation of N-Methyl-d-aspartate Receptors Mediated by Src Kinase

The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways.

Crosstalk Between PSD-95 and JIP1-Mediated Signaling Modules: the Mechanism of MLK3 Activation in Cerebral Ischemia

Neuroprotection Against Focal Ischemic Brain Injury by Inhibition of C-Jun N-terminal Kinase and Attenuation of the Mitochondrial Apoptosis-Signaling Pathway.

Overexpression of the PDZ1 Domain of PSD‐95 Diminishes Ischemic Brain Injury Via Inhibition of the GluR6·PSD‐95·MLK3 Pathway

Neuroprotection Against Neonatal Hypoxia/ischemia-Induced Cerebral Cell Death by Prevention of Calpain-Mediated Mglur1α Truncation

Blockade of the Translocation and Activation of Mitogen-Activated Protein Kinase Kinase 4 (MKK4) Signaling Attenuates Neuronal Damage During Later Ischemia-Reperfusion.

Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis.